R-IDARAM and Immunochemotherapy for Primary CNS Lymphoma
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
Recruiting
Phase 2
Phase 3
Interventional Study
Primary Central Nervous System Lymphoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 100 (estimated)
- Sponsor
- Navy General Hospital, Beijing · Other
Who this trial is looking for
This trial is looking for people with a specific type of brain lymphoma. Participants will receive a combination of treatments to see how effective they are.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with non-Hodgkin's lymphoma.
You may not be able to join if
- I have lymphoma outside of the brain, meninges, CSF, or eyes.
- I am under 18 years old or over 75 years old.
- I have low blood cell counts.
- I have HIV type I infection.
- I have had any previous cancer.
- My kidneys do not work well.
- I have heart failure.
- I have an uncontrolled infection.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria:
* Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).
Exclusion criteria:
* Involved sites other than the brain, meninges, CSF, or the eyes.
* Age less than 18 years or greater than 75 years.
* Inadequate bone marrow capacity (defined as neutrophils\<1.5 ×10\^9…
Contacts